Company intelligence / Profile preview
Alume Biosciences
San Diego, California, United Statesalumebiosciences.com ↗
- Ownership
- Private
- Employees
- ~18
- Development stage
- Phase 3
01
Overview
Alume Biosciences is conducting Phase 3 clinical trials of their lead product ALM-488, a fluorescent peptide-dye conjugate designed to highlight nerves in real time during surgery. They successfully completed Phase 1/2 studies in patients undergoing Head and Neck Surgery in 2021. The Phase 3 studies are being conducted at multiple academic medical centers throughout the US and were projected to be completed in 2023, with FDA submission targeted for 2025[2][7].
- Therapeutic areas
- Other
- Modalities
- Peptide-dye conjugates
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Alume Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alume Biosciences.